May 5, 2008 - Regulatory News: Ipsen (Paris:IPN) today announced that the European Commission granted marketing authorisation for Adenuric(R) (febuxostat) for the treatment of chronic hyperuricaemia in gout. Adenuric(R) thus pioneers the first major treatment alternative for gout, a severe debilitating disease, for more than 40 years.
"Recent surveys confirm that management of gout is often suboptimal, with less than half of patients receiving appropriate lifestyle advice or urate lowering treatment" said Michael Doherty, Professor of Rheumatology at the University of Nottingham (UK) and Co-chair of the 2006 EULAR Task Force for the Recommendations on Diagnosis and Management of Gout. "Recent European (EULAR) Recommendations emphasise the aim of "cure" by lowering serum urate levels below the saturation point for crystal formation. For some patients, the existing urate lowering therapies have limitations in terms of suitability or side effects. The availability of a new effective therapy that allows the therapeutic target to be achieved will improve the physicians armamentarium and ultimately benefit the population of patients with gout."
The details can be read here.
No comments:
Post a Comment